Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination.
The high-dose vaccine is four times more concentrated than the standard Fluzone vaccine, hence providing a higher antibody response. Fluzone HD was approved for use in persons aged =65 years in the US in December 2009.
The superior efficacy of Fluzone High-Dose (HD) (inactivated split virion trivalent influenza vaccine [TIV]; Sanofi Pasteur) compared to standard-dose inactivated influenza vaccines (IIVs) has positioned it as one of the preferred options for the elderly in the US.
Key Topics Covered
- Drug Overview
- Product Profiles
- Fluzone High-Dose: Seasonal influenza vaccines
List of Tables
Table 1: Fluzone High-Dose drug profile
Table 2: Approval history of Fluzone HD for seasonal influenza vaccination
Table 3: Late-phase trials of Fluzone HD for seasonal influenza vaccination
Table 4: Fluzone High-Dose for seasonal influenza - SWOT analysis
For more information about this report visit https://www.researchandmarkets.com/r/trhrui